|
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT
This Securities Purchase Agreement
(this " Agreement ") is dated as of December 17, 2008,
by and among Ardea Biosciences, Inc., a Delaware corporation (the "
Company "), and each purchaser identified on the signature
pages hereto (each, including its successors and assigns, a "
Purchaser " and collectively, the " Purchasers ").
RECITALS
A. The
Company and each Purchaser is executing and delivering this
Agreement in reliance upon the exemption from securities
registration afforded by Section 4(2) of the Securities Act of
1933, as amended (the " Securities Act "), and Rule 506
of Regulation D (" Regulation D ") as promulgated
by the United States Securities and Exchange Commission (the "
Commission ") under the Securities Act.
B. Each
Purchaser, severally and not jointly, wishes to purchase, and the
Company wishes to sell, upon the terms and conditions stated in
this Agreement, (i) that aggregate number of shares of common
stock, par value $0.001 per share (the " Common Stock "), of
the Company, set forth below such Purchaser’s name on the
signature page of this Agreement (which aggregate amount for all
Purchasers together shall be 2,737,336 shares of Common Stock and
shall be collectively referred to herein as the " Shares ")
and warrants substantially in the form attached hereto as
Exhibit A to purchase that aggregate number of shares
of Common Stock set forth below such Purchaser’s name on the
signature page of this Agreement (which aggregate number of
warrants for all Purchasers together shall be warrants to purchase
684,332 shares of Common Stock and shall be collectively referred
to herein as the "Warrants" ). The Shares and the Warrants
are collectively referred to herein as the "Securities."
C.
Contemporaneously with the execution and delivery of this
Agreement, the parties hereto are executing and delivering a
Registration Rights Agreement, substantially in the form attached
hereto as Exhibit B (the " Registration Rights
Agreement ), pursuant to which, among other things, the Company
will agree to provide certain registration rights with respect to
the Shares and the shares of Common Stock issuable upon exercise of
the Warrants (the "Warrant Shares" ) under the Securities
Act and the rules and regulations promulgated thereunder and
applicable state securities laws.
NOW, THEREFORE, IN CONSIDERATION of
the mutual covenants contained in this Agreement, and for other
good and valuable consideration, the receipt and adequacy of which
are hereby acknowledged, the Company and the Purchasers hereby
agree as follows: ARTICLE I.
DEFINITIONS 1.1 Definitions .
In addition to the terms defined elsewhere in this Agreement, for
all purposes of this Agreement, the following terms shall have the
meanings indicated in this Section 1.1:
"
Action " means any action, suit, inquiry, notice of
violation, proceeding (including any partial proceeding such as a
deposition) or investigation pending or, to the Company’s
Knowledge, threatened in writing against the Company, any
Subsidiary or any of their respective properties or any officer,
director or employee of the Company or any Subsidiary acting in his
or her capacity as an officer, director or employee before or by
any federal, state, county, local or foreign court, arbitrator,
governmental or administrative agency, regulatory authority, stock
market, stock exchange or trading facility.
1
"
Affiliate " means, with respect to any Person, any other
Person that, directly or indirectly through one or more
intermediaries, Controls, is controlled by or is under common
control with such Person, as such terms are used in and construed
under Rule 144. With respect to a Purchaser, any investment
fund or managed account that is managed on a discretionary basis by
the same investment manager as such Purchaser will be deemed to be
an Affiliate of such Purchaser.
"
Agreement " shall have the meaning ascribed to such term in
the Preamble.
"
Business Day " means a day, other than a Saturday or Sunday,
on which banks in New York City are open for the general
transaction of business.
"
Buy-In " has the meaning set forth in Section 4.1(f).
"
Buy-In Price " has the meaning set forth in
Section 4.1(f).
"
Closing " means the closing of the purchase and sale of the
Securities pursuant to this Agreement.
"Closing Bid Price" means, for any security as of any date,
the last closing price for such security on the Principal Trading
Market, as reported by Bloomberg, or, if the Principal Trading
Market begins to operate on an extended hours basis and does not
designate the closing bid price then the last bid price of such
security prior to 4:00 p.m., New York City Time, as reported by
Bloomberg, or, if the Principal Trading Market is not the principal
securities exchange or trading market for such security, the last
closing price of such security on the principal securities exchange
or trading market where such security is listed or traded as
reported by Bloomberg, or if the foregoing do not apply, the last
closing price of such security in the over-the-counter market on
the electronic bulletin board for such security as reported by
Bloomberg, or, if no closing bid price is reported for such
security by Bloomberg, the average of the bid prices of any market
makers for such security as reported in the "pink sheets" by Pink
Sheets LLC (formerly the National Quotation Bureau, Inc.). If the
Closing Bid Price cannot be calculated for a security on a
particular date on any of the foregoing bases, the Closing Bid
Price of such security on such date shall be the fair market value
as mutually determined by the Company and the holder. If the
Company and the holder are unable to agree upon the fair market
value of such security, then the Company shall, within two
(2) Business Days submit via facsimile (a) the disputed
determination to an independent, reputable investment bank selected
by the Company and approved by the holder or (b) the disputed
arithmetic calculation to the Company’s independent, outside
accountant. The Company shall cause at its expense the investment
bank or the accountant, as the case may be, to perform the
determinations or calculations and notify the Company and the
holder of the results no later than ten (10) Business Days
from the time it receives the disputed determinations or
calculations. Such investment bank’s or accountant’s
determination or calculation, as the case may be, shall be binding
upon all parties absent demonstrable error. All such determinations
shall be appropriately adjusted for any stock dividend, stock
split, stock combination or other similar transaction during the
applicable calculation period.
"
Closing Date " means the Trading Day when all of the
Transaction Documents have been executed and delivered by the
applicable parties thereto, and all of the conditions set forth in
Sections 2.1, 2.2, 5.1 and 5.2 hereof are satisfied, or such other
date as the parties may agree.
"
Commission " has the meaning set forth in the Recitals.
"
Common Stock " has the meaning set forth in the Recitals,
and also includes any securities into which the Common Stock may
hereafter be reclassified or changed.
2
"
Common Stock Equivalents " means any securities of the
Company or any Subsidiary which would entitle the holder thereof to
acquire at any time Common Stock, including, without limitation,
any debt, preferred stock, rights, options, warrants or other
instrument that is at any time convertible into or exchangeable
for, or otherwise entitles the holder thereof to receive, Common
Stock or other securities that entitle the holder to receive,
directly or indirectly, Common Stock.
"
Company Counsel " means Cooley Godward Kronish LLP.
"
Company Deliverables " has the meaning set forth in
Section 2.2(a).
"
Company’s Knowledge " means with respect to any
statement made to the knowledge of the Company, that the statement
is based upon the actual knowledge of the executive officers of the
Company having responsibility for the matter or matters that are
the subject of the statement.
"
Control " (including the terms "controlling", "controlled
by" or "under common control with") means the possession, direct or
indirect, of the power to direct or cause the direction of the
management and policies of a Person, whether through the ownership
of voting securities, by contract or otherwise.
"
Disclosure Materials " has the meaning set forth in
Section 3.1(h).
"
Effective Date " means the date on which the initial
Registration Statement required by Section 2(a) of the Registration
Rights Agreement applicable to such Purchaser is first declared
effective by the Commission.
"
Environmental Laws " has the meaning set forth in
Section 3.1(l).
"
Exchange Act " means the Securities Exchange Act of 1934, as
amended, or any successor statute, and the rules and regulations
promulgated thereunder.
"
GAAP " means U.S. generally accepted accounting principles,
as applied by the Company.
"
Indemnified Person " has the meaning set forth in
Section 4.8(b).
"
Intellectual Property " has the meaning set forth in
Section 3.1(r).
"
Irrevocable Transfer Agent Instructions " means, with
respect to the Company, the Irrevocable Transfer Agent
Instructions, in the form of Exhibit E , executed by
the Company and delivered to and acknowledged in writing by the
Transfer Agent.
"
Lien " means any lien, charge, claim, encumbrance, security
interest, right of first refusal, preemptive right or other
restrictions of any kind.
"
Material Adverse Effect " means a material adverse effect on
the results of operations, assets, business or financial condition
of the Company, except that any of the following, either alone or
in combination, shall not be deemed a Material Adverse Effect:
(i) effects caused by changes or circumstances affecting
general market conditions in the U.S. economy or which are
generally applicable to the industry in which the Company operates,
(ii) effects resulting from or relating to the announcement or
disclosure of the sale of the Securities or other transactions
contemplated by this Agreement, or (iii) effects caused by any
event, occurrence or condition resulting from or relating to the
taking of any action in accordance with this Agreement.
3
"
Material Contract " means any contract of the Company that
was filed as an exhibit to the SEC Reports pursuant to
Item 601(b)(4) or Item 601(b)(10) of Regulation S-K.
"
Material Permits " has the meaning set forth in
Section 3.1(p).
"
New York Courts " means the state and federal courts sitting
in the City of New York, Borough of Manhattan.
"
Outside Date " means the 30th day following the date of this
Agreement.
"
Person " means an individual, corporation, partnership,
limited liability company, trust, business trust, association,
joint stock company, joint venture, sole proprietorship,
unincorporated organization, governmental authority or any other
form of entity not specifically listed herein.
"
Principal Trading Market " means the Trading Market on which
the Common Stock is primarily listed on and quoted for trading,
which, as of the date of this Agreement and the Closing Date, shall
be the NASDAQ Global Market.
"
Proceeding " means an action, claim, suit, investigation or
proceeding (including, without limitation, an investigation or
partial proceeding, such as a deposition), whether commenced or
threatened.
"
Purchaser Deliverables " has the meaning set forth in
Section 2.2(b).
"
Purchaser Party " has the meaning set forth in
Section 4.8(a).
"
Registration Rights Agreement " has the meaning set forth in
the Recitals.
"
Registration Statement " means a registration statement
meeting the requirements set forth in the Registration Rights
Agreement applicable to such Purchaser and covering the resale by
such Purchaser of the Registrable Securities (as defined in the
Registration Rights Agreement).
"
Required Approvals " has the meaning set forth in
Section 3.1(e).
"
Rule 144 " means Rule 144 promulgated by the
Commission pursuant to the Securities Act, as such Rule may be
amended from time to time, or any similar rule or regulation
hereafter adopted by the Commission having substantially the same
effect as such Rule.
"
SEC Report s" has the meaning set forth in
Section 3.1(h).
"
Secretary’s Certificate " has the meaning set forth in
Section 2.2(a)(vi).
"
Securities Act " means the Securities Act of 1933, as
amended.
"
Share Purchase Price " means $11.14 per share.
"
Short Sales " include, without limitation, all "short sales"
as defined in Rule 200 promulgated under Regulation SHO
under the Exchange Act, whether or not against the box, and all
types of direct and indirect stock pledges, forward sale contracts,
options, puts, calls, short sales, swaps, "put equivalent
positions" (as defined in Rule 16a-1(h) under the Exchange
Act) and similar arrangements (including on a total return basis),
and sales and other transactions through non-U.S. broker dealers or
foreign regulated brokers.
4
"
Subscription Amount " means with respect to each Purchaser,
the aggregate amount to be paid for the Shares and the Warrants
purchased hereunder as indicated on such Purchaser’s
signature page to this Agreement next to the heading "Aggregate
Purchase Price (Subscription Amount)".
"
Subsidiary " means any entity in which the Company, directly
or indirectly, owns capital stock or holds an equity or similar
interest.
"
Trading Affiliate " has the meaning set forth in
Section 3.2(h).
"
Trading Day " means (i) a day on which the Common Stock
is listed or quoted and traded on its Principal Trading Market
(other than the OTC Bulletin Board), or (ii) if the Common
Stock is not listed on a Trading Market (other than the OTC
Bulletin Board), a day on which the Common Stock is traded in the
over-the-counter market, as reported by the OTC Bulletin Board, or
(iii) if the Common Stock is not quoted on any Trading Market,
a day on which the Common Stock is quoted in the over-the-counter
market as reported in the "pink sheets" by Pink Sheets LLC (or any
similar organization or agency succeeding to its functions of
reporting prices); provided , that in the event that the
Common Stock is not listed or quoted as set forth in (i),
(ii) and (iii) hereof, then Trading Day shall mean a
Business Day.
"
Trading Market " means whichever of the New York Stock
Exchange, the American Stock Exchange, the NASDAQ Global Select
Market, the NASDAQ Global Market, the NASDAQ Capital Market or the
OTC Bulletin Board on which the Common Stock is listed or quoted
for trading on the date in question.
"
Transaction Documents " means this Agreement, the schedules
and exhibits attached hereto, the Warrants, the Registration Rights
Agreement, the Irrevocable Transfer Agent Instructions and any
other documents or agreements executed in connection with the
transactions contemplated hereunder.
"
Transfer Agent " means Computershare Trust Company N.A., or
any successor transfer agent for the Company. ARTICLE II.
PURCHASE AND SALE 2.1 Closing
. (a)
Amount . Subject to the terms and conditions set forth in
this Agreement, at the Closing, the Company shall issue and sell to
each Purchaser, and each Purchaser shall, severally and not
jointly, purchase from the Company, such number of (A) Shares
equal to the quotient resulting from dividing (i) the
Subscription Amount for such Purchaser by (ii) the sum of
(y) the Share Purchase Price and (z) 0.03125, rounded
down to the nearest whole Share and (B) Warrants to purchase
such number of Warrant Shares equal to the quotient resulting from
muliplying (i) the number of Shares to be acquired by such
Purchaser pursuant hereto, by (ii) 0.25, rounded down to the
nearest whole Warrant Share.
(b)
Closing . The Closing of the purchase and sale of the
Securities shall take place at the offices of Cooley Godward
Kronish LLP, 4401 Eastgate Mall, San Diego, California on the
Closing Date or at such other locations or remotely by facsimile
transmission or other electronic means as the parties may mutually
agree.
(c)
Form of Payment . On the Closing Date (i) each
Purchaser that has agreed to wire funds directly to the Company
shall wire such Purchaser’s Subscription Amount to the
Company in accordance with the written directions from the Company,
and (ii) the Company shall (A) deliver or cause to
5
be delivered to each Purchaser a duly executed Warrant to
purchase the number of Warrant Shares set forth below such
Purchaser’s name on the signature page of this Agreement and
(B) irrevocably instruct the Transfer Agent to deliver to each
Purchaser one or more stock certificates, free and clear of all
restrictive and other legends (except as expressly provided in
Section 4.1(b) hereof), evidencing the number of Shares such
Purchaser is purchasing as is set forth on such Purchaser’s
signature page to this Agreement next to the heading "Number of
Shares to be Acquired", within three (3) Business Days after
the Closing, duly executed on behalf of the Company and registered
in the name of such Purchaser. 2.2
Closing Deliveries .
(a) On
or prior to the Closing, the Company shall issue, deliver or cause
to be delivered to each Purchaser the following (the " Company
Deliverables "):
(i) this
Agreement, duly executed by the Company;
(ii) facsimile
copies of one or more stock certificates, free and clear of all
restrictive and other legends (except as provided in
Section 4.1(b) hereof), evidencing the Shares
subscribed for by Purchaser hereunder, registered in the name of
such Purchaser as set forth on the Stock Certificate Questionnaire
included as Exhibit C-2 hereto (the " Stock
Certificates "), with the original Stock Certificates sent
within three (3) Business Days of Closing;
(iii) a
Warrant to purchase the number of Warrant Shares set forth below
such Purchaser’s name on the signature page of this
Agreement, duly executed by the Company;
(iv) a
legal opinion of Company Counsel, dated as of the Closing Date and
in the form attached hereto as Exhibit D , executed by
such counsel and addressed to the Purchasers;
(v) the
Registration Rights Agreement, duly executed by the Company;
(vi) duly
executed Irrevocable Transfer Agent Instructions acknowledged in
writing by the Transfer Agent;
(vii) a
certificate of the Secretary of the Company (the "
Secretary’s Certificate "), dated as of the Closing
Date, certifying (a) the resolutions adopted by the Board of
Directors of the Company or a duly authorized committee thereof
approving the transactions contemplated by this Agreement and the
other Transaction Documents and the issuance of the Securities,
(b) the current versions of the certificate of incorporation
and by-laws of the Company, each as amended, and (c) as to the
signatures and authority of persons signing the Transaction
Documents and related documents on behalf of the Company, in the
form attached hereto as Exhibit F ;
(viii) the
Compliance Certificate referred to in Section 5.1(g);
(ix) a
certificate evidencing the formation and good standing of the
Company in its jurisdiction of formation issued by the Secretary of
State (or comparable office) of such jurisdiction, as of a date
within five (5) Business Days of the Closing Date;
(x) a
certificate evidencing the Company’s qualification as a
foreign corporation and good standing issued by the Secretary of
State of the State of California, as of a date within ten (10)
Business Days of the Closing Date; and
6
(xi) a
certified copy of the certificate of incorporation, as certified by
the Secretary of State of the State (or comparable office) of the
Company’s jurisdiction of formation, as of a date within ten
(10) Business Days of the Closing Date.
(b) On
or prior to the Closing, each Purchaser shall deliver or cause to
be delivered to the Company the following (the " Purchaser
Deliverables "):
(i) this
Agreement, duly executed by such Purchaser;
(ii) its
Subscription Amount, in United States dollars and in immediately
available funds, in the amount set forth as the "Purchase Price"
indicated below such Purchaser’s name on the applicable
signature page hereto under the heading "Aggregate Purchase Price
(Subscription Amount)" by wire transfer to the escrow account set
forth on Exhibit H attached hereto or to the account of
the Company pursuant to Section 2.1(c);
(iii) the
Registration Rights Agreement, duly executed by such Purchaser;
(iv) a
fully completed and duly executed Selling Stockholder Questionnaire
in the form attached as Annex B to the Registration Rights
Agreement; and
(v) a
fully completed and duly executed Accredited Investor
Questionnaire, reasonably satisfactory to the Company, and Stock
Certificate Questionnaire in the forms attached hereto as
Exhibits B-1 and B-2 , respectively. ARTICLE
III.
REPRESENTATIONS AND WARRANTIES 3.1
Representations and Warranties of the Company . The Company
hereby represents and warrants as of the date hereof and the
Closing Date (except for the representations and warranties that
speak as of a specific date, which shall be made as of such date),
to each of the Purchasers that, except as set forth in the
Schedules delivered herewith or disclosed in the SEC Reports:
(a)
Subsidiaries . The Company has no direct or indirect
Subsidiaries other than those listed in Schedule 3.1(a)
hereto. Except as disclosed in Schedule 3.1(a) hereto,
the Company owns, directly or indirectly, all of the capital stock
or comparable equity interests of each Subsidiary free and clear of
any and all Liens which could reasonably be expected to have a
Material Adverse Effect, and all the issued and outstanding shares
of capital stock or comparable equity interest of each Subsidiary
are validly issued and are fully paid, non-assessable and free of
preemptive and similar rights to subscribe for or purchase
securities.
(b)
Organization and Qualification . The Company and each of its
Subsidiaries is an entity duly incorporated or otherwise organized,
validly existing and in good standing under the laws of the
jurisdiction of its incorporation or organization (as applicable),
with the requisite corporate power and authority to own or lease
and use its properties and assets and to carry on its business as
currently conducted. Neither the Company nor any Subsidiary is in
violation of any of the provisions of its respective certificate or
articles of incorporation, bylaws or other organizational or
charter documents. The Company and each of its Subsidiaries is duly
qualified to conduct business and is in good standing as a foreign
corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such
qualification necessary, except where the failure to be so
qualified or in good standing, as the case may be, would not have a
Material Adverse Effect.
7
(c)
Authorization; Enforcement; Validity . The Company has the
requisite corporate power and authority to enter into and to
consummate the transactions contemplated by each of the Transaction
Documents to which it is a party and otherwise to carry out its
obligations hereunder and thereunder. The Company’s execution
and delivery of each of the Transaction Documents to which it is a
party and the consummation by it of the transactions contemplated
hereby and thereby (including, but not limited to, the sale and
delivery of the Securities and the reservation for issuance and the
subsequent issuance of the Warrant Shares) have been duly
authorized by all necessary corporate action on the part of the
Company, and no further corporate action is required by the
Company, its Board of Directors or its stockholders in connection
therewith other than in connection with the Required Approvals.
Each of the Transaction Documents to which it is a party has been
(or upon delivery will have been) duly executed by the Company and
is, or when delivered in accordance with the terms hereof, will
constitute the legal, valid and binding obligation of the Company
enforceable against the Company in accordance with its terms,
except (i) as such enforceability may be limited by applicable
bankruptcy, insolvency, reorganization, moratorium, liquidation or
similar laws relating to, or affecting generally the enforcement
of, creditors’ rights and remedies or by other equitable
principles of general , (ii) as limited by laws relating to
the availability of specific performance, injunctive relief or
other equitable remedies and (iii) insofar as indemnification
and contribution provisions may be limited by applicable law.
Except for Material Contracts and as set forth on
Schedule 3.1(c) hereto, there are no stockholder
agreements, voting agreements, or other similar arrangements with
respect to the Company’s capital stock to which the Company
is a party or, to the Company’s Knowledge, between or among
any of the Company’s stockholders.
(d)
No Conflicts . The execution, delivery and performance by
the Company of the Transaction Documents to which it is a party and
the consummation by the Company of the transactions contemplated
hereby or thereby (including, without limitation, the issuance of
the Securities and the Warrant Shares) do not and will not
(i) conflict with or violate any provisions of the
Company’s or any Subsidiary’s certificate or articles
of incorporation, bylaws or otherwise result in a violation of the
organizational documents of the Company, (ii) conflict with,
or constitute a default (or an event that with notice or lapse of
time or both would result in a default) under, result in the
creation of any Lien upon any of the properties or assets of the
Company or give to others any rights of termination, amendment,
acceleration or cancellation (with or without notice, lapse of time
or both) of, any Material Contract, or (iii) subject to the
Required Approvals, conflict with or result in a violation of any
law, rule, regulation, order, judgment, injunction, decree or other
restriction of any court or governmental authority to which the
Company is subject (including federal and state securities laws and
regulations and the rules and regulations, assuming the correctness
of the representations and warranties made by the Purchasers
herein, of any self-regulatory organization to which the Company or
its securities are subject, including all applicable Trading
Markets), or by which any property or asset of the Company is bound
or affected, except in the case of clauses (ii) and
(iii) such as would not, individually or in the aggregate,
have a Material Adverse Effect.
(e)
Filings, Consents and Approvals . Neither the Company nor
any of its Subsidiaries is required to obtain any consent, waiver,
authorization or order of, give any notice to, or make any filing
or registration with, any court or other federal, state, local or
other governmental authority or other Person in connection with the
execution, delivery and performance by the Company of the
Transaction Documents (including the issuance of the Securities and
the Warrant Shares), other than (i) the filing with the
Commission of one or more Registration Statements in accordance
with the requirements of the Registration Rights Agreement,
(ii) filings required by applicable state securities laws,
(iii) the filing of a Notice of Sale of Securities on
Form D with the Commission under Regulation D of the
Securities Act, (iv) the filing of any requisite notices
and/or application(s) to the Principal Trading Market for the
issuance and sale of the Common Stock and the listing of the Common
Stock for trading or quotation, as the case may be, thereon in the
time and manner required thereby, (v) the filings required in
accordance with Section 4.7 of this Agreement and
(vi) those that have been made or obtained prior to the date
of this Agreement (collectively, the " Required Approvals
").
8
(f)
Issuance of the Shares and the Warrant Shares . The Shares
and the Warrant Shares have been duly authorized and, when issued
and paid for in accordance with the terms of the Transaction
Documents, will be duly and validly issued, fully paid and
nonassessable and free and clear of all Liens, other than
restrictions on transfer provided for in the Transaction Documents
or imposed by applicable securities laws, and shall not be subject
to preemptive or similar rights. Assuming the accuracy of the
representations and warranties of the Purchasers in this Agreement,
the Shares, Warrants and the Warrant Shares will be issued in
compliance with all applicable federal and state securities laws.
The Warrants have been duly authorized and, when issued and paid
for in accordance with the terms of the Transaction Documents, will
be duly and validly issued, free and clear of all Liens, other than
restrictions on transfer provided for in the Transaction Documents
or imposed by applicable securities laws, and shall not be subject
to preemptive or similar rights of stockholders. As of the Closing
Date, the Company shall have reserved from its duly authorized
capital stock the number of shares of Common Stock issuable upon
exercise of the Warrants (without taking into account any
limitations on the exercise of the Warrants set forth in the
Warrants). The Company shall, so long as any of the Warrants are
outstanding, take all action necessary to reserve and keep
available out of its authorized and unissued capital stock, solely
for the purpose of effecting the exercise of the Warrants, 100% of
the number of shares of Common Stock issuable upon exercise of the
Warrants.
(g)
Capitalization . The number of shares and type of all
authorized, issued and outstanding capital stock, options and other
securities of the Company (whether or not presently convertible
into or exercisable or exchangeable for shares of capital stock of
the Company) has been set forth in the SEC Reports and has changed
since the date of such SEC Reports only due to stock grants or
other equity awards or stock option and warrant exercises that do
not, individually or in the aggregate, have a material effect on
the issued and outstanding capital stock, options and other
securities. All of the outstanding shares of capital stock of the
Company are duly authorized, validly issued, fully paid and
non-assessable, have been issued in compliance in all material
respects with all applicable federal and state securities laws, and
none of such outstanding shares was issued in violation of any
preemptive rights or similar rights to subscribe for or purchase
any capital stock of the Company. Except as specified in the SEC
Reports: (i) no shares of the Company’s outstanding
capital stock are subject to preemptive rights or any other similar
rights; (ii) there are no outstanding options, warrants,
scrip, rights to subscribe to, calls or commitments of any
character whatsoever relating to, or securities or rights
convertible into, or exercisable or exchangeable for, any shares of
capital stock of the Company, or contracts, commitments,
understandings or arrangements by which the Company is or may
become bound to issue additional shares of capital stock of the
Company or options, warrants, scrip, rights to subscribe to, calls
or commitments of any character whatsoever relating to, or
securities or rights convertible into, or exercisable or
exchangeable for, any shares of capital stock of the Company, other
than those issued or granted pursuant to Material Contracts or
equity or incentive plans or arrangements described in the SEC
Reports; (iii) there are no material outstanding debt
securities, notes, credit agreements, credit facilities or other
agreements, documents or instruments evidencing indebtedness of the
Company or by which the Company is bound; (iv) to the
Company’s Knowledge, there are no financing statements
securing obligations in any material amounts, either singly or in
the aggregate, filed in connection with the Company; (v) there
are no agreements or arrangements under which the Company is
obligated to register the sale of any of their securities under the
Securities Act (except the Registration Rights Agreement);
(vi) there are no outstanding securities or instruments of the
Company or which contain any redemption or similar provisions, and
there are no contracts, commitments, understandings or arrangements
by which the Company is or may become bound to redeem a security of
the Company; (vii) there are no securities or instruments
containing anti-dilution or similar provisions that will be
triggered by the issuance of the Shares; (viii) the Company
does not have any stock appreciation rights or "phantom stock"
plans or agreements or any similar plan or agreement; and
(ix) the Company has no liabilities or obligations required to
be disclosed in the SEC Reports but not so disclosed in the SEC
Reports, other than those incurred in the ordinary course of the
Company’s businesses and which, individually or in the
aggregate, do not or would not have a Material Adverse Effect.
9
(h)
SEC Reports . The Company has filed all reports, schedules,
forms, statements and other documents required to be filed by it
under the Exchange Act, including pursuant to Section 13(a) or
15(d) thereof, for the twelve months preceding the date hereof (or
such shorter period as the Company was required by law or
regulation to file such material) (the foregoing materials,
including the exhibits thereto and documents incorporated by
reference therein, being collectively referred to herein as the "
SEC Reports " and together with this Agreement and the
Schedules to this Agreement (if any), the " Disclosure
Materials "), on a timely basis or has received a valid
extension of such time of filing and has filed any such SEC Reports
prior to the expiration of any such extension. As of their
respective filing dates, or to the extent corrected by a subsequent
restatement, the SEC Reports complied in all material respects with
the requirements of the Securities Act and the Exchange Act and the
rules and regulations of the Commission promulgated thereunder, and
none of the SEC Reports, when filed, contained any untrue statement
of a material fact or omitted to state a material fact required to
be stated therein or necessary in order to make the statements
therein, in light of the circumstances under which they were made,
not misleading.
(i)
Financial Statements . The financial statements of the
Company included in the SEC Reports comply in all material respects
with applicable accounting requirements and the rules and
regulations of the Commission with respect thereto as in effect at
the time of filing (or to the extent corrected by a subsequent
restatement). Such financial statements have been prepared in
accordance with GAAP applied on a consistent basis during the
periods involved, except as may be otherwise specified in such
financial statements or the notes thereto and except that unaudited
financial statements may not contain all footnotes required by
GAAP, and fairly present in all material respects the financial
position of the Company and its consolidated subsidiaries taken as
a whole as of and for the dates thereof and the results of
operations and cash flows for the periods then ended, subject, in
the case of unaudited statements, to normal, year-end audit
adjustments.
(j)
Tax Matters . The Company (i) has prepared and filed
all foreign, federal and state income and all other tax returns,
reports and declarations required by any jurisdiction to which it
is subject, (ii) has paid all taxes and other governmental
assessments and charges that are material in amount, shown or
determined to be due on such returns, reports and declarations,
except those being contested in good faith, with respect to which
adequate reserves have been set aside on the books of the Company
and (iii) has set aside on its books provisions reasonably
adequate for the payment of all taxes for periods subsequent to the
periods to which such returns, reports or declarations apply,
except, in the case of clauses (i) and (ii) above, where
the failure to so pay or file any such tax, assessment, charge or
return would not have a Material Adverse Effect.
(k)
Material Changes . Since the date of the latest financial
statements included within the SEC Reports, except as specifically
disclosed in the SEC Reports or as set forth in
Schedule 3.1(k) hereto, (i) there have been no
events, occurrences or developments that have had or would
reasonably be expected to have, either individually or in the
aggregate, a Material Adverse Effect, (ii) the Company has not
incurred any material liabilities (contingent or otherwise) other
than (A) trade payables, accrued expenses and other
liabilities incurred in the ordinary course of business consistent
with past practice and (B) liabilities not required to be
reflected in the Company’s financial statements pursuant to
GAAP or required to be disclosed in filings made with the
Commission, (iii) the Company has not altered materially its
method of accounting or the manner in which it keeps its accounting
books and records, (iv) the Company has not declared or made
any dividend or distribution of cash or other property to its
stockholders or purchased, redeemed or made any agreements to
purchase or redeem any shares of its capital stock (other than in
connection with repurchases of unvested stock issued to employees
of the Company), (v) the Company has not issued any equity
securities to any officer, director or Affiliate, except Common
Stock issued in the ordinary course as dividends on outstanding
preferred stock or issued pursuant to existing Company stock option
or stock purchase plans or executive and director corporate
arrangements disclosed in the SEC Reports and (vi) there has
not been any material change or amendment to, or any waiver of any
material right
10
by the Company under, any Material Contract under which the
Company or any of its Subsidiaries is bound or subject. Except for
the transactions contemplated by this Agreement or as set forth in
Schedule 3.1(k) hereto, no event, liability or
development has occurred or exists with respect to the Company or
its Subsidiaries or their respective business, properties,
operations or financial condition that would be required to be
disclosed by the Company under applicable securities laws at the
time this representation is made that has not been publicly
disclosed at least one Trading Day prior to the date that this
representation is made.
(l)
Environmental Matters . To the Company’s Knowledge,
neither the Company nor any of its Subsidiaries (i) is in
violation of any statute, rule, regulation, decision or order of
any governmental agency or body or any court, domestic or foreign,
relating to the use, disposal or release of hazardous or toxic
substances or relating to the protection or restoration of the
environment or human exposure to hazardous or toxic substances
(collectively, " Environmental Laws "), (ii) owns or
operates any real property contaminated with any substance that is
in violation of any Environmental Laws, (iii) is liable for
any off-site disposal or contamination pursuant to any
Environmental Laws, or (iv) is subject to any claim relating
to any Environmental Laws; which violation, contamination,
liability or claim has had or would have, individually or in the
aggregate, a Material Adverse Effect; and, to the Company’s
Knowledge, there is no pending or threatened investigation that
might lead to such a claim.
(m)
Litigation . To the Company’s Knowledge, there is no
Action which (i) adversely affects or challenges the legality,
validity or enforceability of any of the Transaction Documents or
the Securities or (ii) except as specifically disclosed in the
SEC Reports, could, if there were an unfavorable decision,
individually or in the aggregate, have a Material Adverse Effect.
Neither the Company nor any Subsidiary, nor to the Company’s
Knowledge any director or officer thereof, is or has been the
subject of any Action involving a claim of violation of or
liability under federal or state securities laws or a claim of
breach of fiduciary duty. There has not been, and to the
Company’s Knowledge there is not pending or contemplated, any
investigation by the Commission involving the Company or any
current or former director or officer of the Company. The
Commission has not issued any stop order or other order suspending
the effectiveness of any registration statement filed by the
Company or any of its Subsidiaries under the Exchange Act or the
Securities Act.
(n)
Employment Matters . No material labor dispute exists or, to
the Company’s Knowledge, is imminent with respect to any of
the employees of the Company which would have a Material Adverse
Effect. None of the Company’s employees is a member of a
union that relates to such employee’s relationship with the
Company, and neither the Company nor any of its Subsidiaries is a
party to a collective bargaining agreement, and the Company and
each Subsidiary believes that its relationship with its employees
is good. No executive officer of the Company (as defined in Rule
501(f) of the 1933 Act) has notified the Company that such officer
intends to leave the Company or otherwise terminate such
officer’s employment with the Company. To the Company’s
Knowledge, it is in compliance with all U.S. federal, state, local
and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages
and hours, except where the failure to be in compliance would not,
individually or in the aggregate, have a Material Adverse Effect.
(o)
Compliance . Neither the Company nor any of its Subsidiaries
(i) is in default under or in violation of (and no event has
occurred that has not been waived that, with notice or lapse of
time or both, would result in a default by the Company or any of
its Subsidiaries under), nor has the Company or any of its
Subsidiaries received written notice of a claim that it is in
default under or that it is in violation of, any Material Contract
(whether or not such default or violation has been waived),
(ii) is in violation of any order of which the Company has
been made aware in writing of any court, arbitrator or governmental
body having jurisdiction over the Company or its properties or
assets, or (iii) is in violation of, or in receipt of written
notice that it is in violation of, any statute, rule or regulation
of any governmental authority applicable to the Company, except in
each case as would not, individually or in the aggregate, have a
Material Adverse Effect.
11
(p)
Regulatory Permits . The Company and each of its
Subsidiaries possess or have applied for all certificates,
authorizations and permits issued by the appropriate federal,
state, local or foreign regulatory authorities necessary to conduct
its respective businesses as currently conducted and as described
in the SEC Reports, except where the failure to possess such
permits, individually or in the aggregate, has not and would not
have, individually or in the aggregate, a Material Adverse Effect
(" Material Permits "), and (i) neither the Company nor
any of its Subsidiaries has received any notice in writing of
proceedings relating to the revocation or material adverse
modification of any such Material Permits and (ii) the Company
is unaware of any facts or circumstances that would give rise to
the revocation or material adverse modification of any Material
Permits.
(q)
Title to Assets . The Company and its Subsidiaries do not
own any real property. The Company and its Subsidiaries have good
and marketable title to all tangible personal property owned by
them which is material to the business of the Company and its
Subsidiaries, taken as whole, in each case free and clear of all
Liens except such as do not materially affect the value of such
property and do not interfere with the use made and proposed to be
made of such property by the Company and any of its Subsidiaries.
Any real property and facilities held under lease by the Company
and any of its Subsidiaries are held by them under valid,
subsisting and enforceable leases with such exceptions as are not
material and do not interfere with the use made and proposed to be
made of such property and buildings by the Company and its
Subsidiaries.
(r)
Patents and Trademarks . To the Company’s Knowledge,
the Company and its Subsidiaries own, possess, license or have
other rights to use all foreign and domestic patents, patent
applications, trade and service marks, trade and service mark
registrations, trade names, copyrights, inventions, trade secrets,
technology, Internet domain names, know-how and other intellectual
property (collectively, the " Intellectual Property ")
necessary for the conduct of their respective businesses as now
conducted or as proposed to be conducted. Except as set forth in
the SEC Reports and except where such violations or infringements
would not have, either individually or in the aggregate, a Material
Adverse Effect, (i) to the Company’s Knowledge, there
are no rights of third parties to any such Intellectual Property;
(ii) to the Company’s Knowledge, there is no
infringement by third parties of any such Intellectual Property;
(iii) to the Company’s Knowledge, there is no pending or
threatened action, suit, proceeding or claim by others challenging
the Company’s and its Subsidiaries’ rights in or to any
such Intellectual Property; (iv) to the Company’s
Knowledge, there is no pending or threatened action, suit,
proceeding or claim by others challenging the validity or scope of
any such Intellectual Property; and (v) to the Company’s
Knowledge, there is no pending or threatened action, suit,
proceeding or claim by others that the Company and/or any
Subsidiary infringes or otherwise violates any patent, trademark,
copyright, trade secret or other proprietary rights of others.
(s)
Insurance . The Company and each of the Subsidiaries are
insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as the Company believes
to be prudent and customary in the businesses and locations in
which the Company and the Subsidiaries are engaged. Neither the
Company nor any of its Subsidiaries has received any notice of
cancellation of any such insurance, nor, to the Company’s
Knowledge, will it or any Subsidiary be unable to renew their
respective existing insurance coverage as and when such coverage
expires or to obtain similar coverage from similar insurers as may
be necessary to continue its business.
(t)
Transactions With Affiliates and Employees . Except as set
forth in the SEC Reports and other than the grant of stock options
or other equity awards that are not individually or in the
aggregate material in amount, none of the officers or directors of
the Company and, to the Company’s Knowledge, none of the
employees of the Company, is presently a party to any transaction
with the Company or any Subsidiary or to a presently contemplated
transaction (other than for services as employees, officers and
12
directors) that would be required to be disclosed pursuant to
Item 404 of Regulation S-K promulgated under the
Securities Act.
(u)
Internal Accounting Controls . The Company maintains a
system of internal accounting controls sufficient to provide
reasonable assurance that (i) transactions are executed in
accordance with management’s general or specific
authorizations, (ii) transactions are recorded as necessary to
permit preparation of financial statements in conformity with GAAP
and to maintain asset and liability accountability,
(iii) access to assets or incurrence of liabilities is
permitted only in accordance with management’s general or
specific authorization, and (iv) the recorded accountability
for assets and liabilities is compared with the existing assets and
liabilities at reasonable intervals and in the Company’s good
faith judgment appropriate action is taken with respect to any
differences. Since the most recently filed periodic report under
the Exchange Act, there have been no changes in the Company’s
internal control over financial reporting (as such term is defined
in the Exchange Act) that have materially affected, or is
reasonably likely to materially affect, the Company’s
internal control over financial reporting.
(v)
Sarbanes-Oxley; Disclosure Controls . To the Company’s
Knowledge, the Company is in compliance in all material respects
with all of the provisions of the Sarbanes-Oxley Act of 2002 which
are applicable to it, except where such noncompliance would not
have, individually or in the aggregate, a Material Adverse Effect.
The Company maintains disclosure controls and procedures (as such
term is defined in Rule 13a-15(e) and 15d-15(e) under the
Exchange Act).
(w)
Certain Fees . No person or entity will have, as a result of
the transactions contemplated by this Agreement, any valid right,
interest or claim against or upon the Company or a Purchaser for
any commission, fee or other compensation pursuant to any
agreement, arrangement or understanding entered into by or on
behalf of the Company with respect to the offer and sale of the
Securities or the Warrant Shares. The Company shall indemnify, pay,
and hold each Purchaser harmless against, any liability, loss or
expense (including, without limitation, attorneys’ fees and
out-of-pocket expenses) arising in connection with any such right,
interest or claim.
(x)
Private Placement . Assuming the accuracy of the
Purchasers’ representations and warranties set forth in
Section 3.2 of this Agreement and the accuracy of the
information disclosed in the Accredited Investor Questionnaires, no
registration under the Securities Act is required for the offer and
sale of the Securities or the Warrant Shares by the Company to the
Purchasers under the Transaction Documents.
(y)
Registration Rights . Other than as set forth in the SEC
Reports and other than each of the Purchasers or as set forth in
Schedule 3.1(y) hereto, no Person has any right to
cause the Company to effect the registration under the Securities
Act of any securities of the Company other than those securities
which are currently registered on an effective registration
statement on file with the Commission.
(z)
No Integrated Offering . Assuming the accuracy of the
Purchasers’ representations and warranties set forth in
Section 3.2, none of the Company, its Subsidiaries nor, to the
Company’s Knowledge, any of its Affiliates or any Person
acting on its behalf has, directly or indirectly, at any time
within the past six months, made any offers or sales of any Company
security or solicited any offers to buy any security under
circumstances that would (i) eliminate the availability of the
exemption from registration under Regulation D under the
Securities Act in connection with the offer and sale by the Company
of the Securities as contemplated hereby or (ii) cause the offering
of the Securities pursuant to the Transaction Documents to be
integrated with prior offerings by the Company for purposes of any
applicable law, regulation or stockholder approval provisions,
including, without limitation, under the rules and regulations of
any Trading Market on which any of the securities of the Company
are listed or designated. Neither the Company nor, to the
Company’s Knowledge, any person acting on behalf of the
Company has offered or sold any of the Securities by any form of
general solicitation or general advertising.
13
(aa)
Listing and Maintenance Requirements . The Company’s
Common Stock is registered pursuant to Section 12(b) or 12(g) of
the Exchange Act, and the Company has taken no action designed to
terminate the registration of the Common Stock under the Exchange
Act nor has the Company received any notification that the
Commission is contemplating terminating such registration. The
Company has not, in the twelve (12) months preceding the date
hereof, received written notice from any Trading Market on which
the Common Stock is listed or quoted to the effect that the Company
is not in compliance with the listing or maintenance requirements
of such Trading Market. The Company is in compliance in all
material respects with the listing and maintenance requirements for
continued trading of the Common Stock on the Principal Trading
Market.
(bb)
Investment Company . Neither the Company nor any of its
Subsidiaries is required to be registered as, and is not an
Affiliate of, and immediately following the Closing will not be
required to register as, an "investment company" within the meaning
of the Investment Company Act of 1940, as amended.
(cc)
Questionable Payments . To the Company’s Knowledge,
neither the Company nor any of its Subsidiaries, nor any directors,
officers, employees, agents or other Persons acting at the
direction of the Company has, in the course of its actions for, or
on behalf of, the Company: (i) directly or indirectly, used any
material corporate funds for unlawful contributions, gifts,
entertainment or other unlawful expenses relating to foreign or
domestic political activity; (ii) made any material direct or
indirect unlawful payments to any foreign or domestic governmental
officials or employees or to any foreign or domestic political
parties or campaigns from corporate funds; (iii) violated in
any material respect any provision of the Foreign Corrupt Practices
Act of 1977, as amended, or (iv) made any other material
unlawful bribe, rebate, payoff, influence payment, kickback or
other material unlawful payment to any foreign or domestic
government official or employee.
(dd)
Application of Takeover Protections; Rights Agreements . The
Company and its board of directors have taken all necessary action,
if any, in order to render inapplicable any control share
acquisition, business combination, poison pill (including any
distribution under a rights agreement) or other similar
anti-takeover provision under the Company’s charter documents
or the laws of its state of incorporation that is applicable to any
of the Purchasers as a result of the Purchasers and the Company
fulfilling their obligations or exercising their rights under the
Transaction Documents, including, without limitation, the
Company’s issuance of the Securities and the
Purchasers’ ownership of the Securities. The Company has not
adopted a stockholder rights plan or similar arrangement relating
to accumulations of beneficial ownership of Common Stock or a
change in control of the Company.
(ee)
Disclosure . To the Company’s Knowledge, no event or
circumstance has occurred or information exists with respect to the
Company or any of its Subsidiaries or its or their business,
properties, operations or financial conditions, which, under
applicable law, rule or regulation, requires public disclosure or
announcement by the Company but which has not been so publicly
announced or disclosed (assuming for this purpose that the
Company’s reports filed under the Exchange Act are being
incorporated into an effective registration statement filed by the
Company under the Securities Act), except for the announcement of
this Agreement and related transactions and as may be disclosed on
the Form 8-K filed pursuant to Section 4.6.
(ff)
Off Balance Sheet Arrangements . There is no transaction,
arrangement, or other relationship between the Company (or any
Subsidiary) and an unconsolidated or other off balance sheet entity
that is required to be disclosed by the Company in its Exchange Act
filings and is not so disclosed and would have a Material Adverse
Effect.
14
(gg)
Acknowledgment Regarding Purchasers’ Purchase of
Securities . The Company acknowledges and agrees that each of
the Purchasers is acting solely in the capacity of an arm’s
length purchaser with respect to the Transaction Documents and the
transactions contemplated hereby and thereby. The Company further
acknowledges that no Purchaser is acting as a financial advisor or
fiduciary of the Company (or in any similar capacity) with respect
to the Transaction Documents and the transactions contemplated
thereby and any advice given by any Purchaser or any of their
respective representatives or agents in connection with the
Transaction Documents and the transactions contemplated thereby is
merely incidental to the Purchasers’ purchase of the
Securities.
(hh)
Regulation M Compliance . In the last thirty
(30) calendar days, the Company has not, and to the
Company’s Knowledge no one acting on its behalf has,
(i) taken, directly or indirectly, any action designed to
cause or to result in the stabilization or manipulation of the
price of any security of the Company to facilitate the sale or
resale of any of the Securities, (ii) sold, bid for,
purchased, or paid any compensation for soliciting purchases of,
any of the securities of the Company or (iii) paid or agreed
to pay to any Person any compensation for soliciting another to
purchase any other securities of the Company.
(ii)
OFAC . Neither the Company nor any Subsidiary nor, to the
Company’s Knowledge, any director, officer, agent, employee,
Affiliate or Person acting on behalf of the Company or any
Subsidiary is currently subject to any U.S. sanctions administered
by the Office of Foreign Assets Control of the U.S. Treasury
Department (" OFAC "); and the Company will not knowingly
directly or indirectly use the proceeds of the sale of the
Securities, or lend, contribute or otherwise make available such
proceeds to any Subsidiary, joint venture partner or other Person
or entity, towards any sales or operations in Cuba, Iran, Syria,
Sudan, Myanmar or any other country sanctioned by OFAC or for the
purpose of financing the activities of any Person currently subject
to any U.S. sanctions administered by OFAC.
(jj)
Money Laundering Laws . To the Company’s Knowledge,
the operations of each of the Company and any Subsidiary are and
have been conducted at all times in compliance with the money
laundering statutes of applicable jurisdictions, the rules and
regulations thereunder and any related or similar rules,
regulations or guidelines, issued, administered or enforced by any
applicable governmental agency (collectively, the " Money
Laundering Laws ") and to the Company’s Knowledge, no
action, suit or proceeding by or before any court or governmental
agency, authority or body or any arbitrator involving the Company
and/or any Subsidiary with respect to the Money Laundering Laws is
pending or threatened.
(kk)
FDA . To the Company’s Knowledge, there is no pending,
completed or threatened, action (including any lawsuit,
arbitration, or legal or administrative or regulatory proceeding,
charge, complaint, or investigation) against the Company or any of
its Subsidiaries, and none of the Company or any of its
Subsidiaries has received any notice, warning letter or other
communication from the U.S. Food and Drug Administration ("
FDA ") or any other governmental entity, which
(i) contests the premarket clearance, licensure, registration,
or approval of, the uses of, the distribution of, the manufacturing
or packaging of, the testing of, the sale of, or the labeling and
promotion of any product subject to the jurisdiction of the FDA
under the Federal Food, Drug and Cosmetic Act, as amended, and the
regulations thereunder that is manufactured, packaged, labeled,
tested, distributed, sold, and/or marketed by the Company or any of
its Subsidiaries (each such product, a " Pharmaceutical
Product "), (ii) imposes a clinical hold on any clinical
investigation by the Company or any of its Subsidiaries,
(iii) enjoins production at any facility of the Company or any
of its Subsidiaries, (iv) enters or proposes to enter into a
consent decree of permanent injunction with the Company or any of
its Subsidiaries, or (v) otherwise alleges any violation of
any laws, rules or regulations by the Company or any of its
Subsidiaries, and which, either individually or in the aggregate,
would have a Material Adverse Effect. The Company has not been
informed in writing by the FDA that the FDA will prohibit the
marketing, sale, license or use in the United States of any product
proposed to be developed, produced or marketed by the Company.
15
(ll)
No Additional Agreements . The Company does not have any
agreement or understanding with any Purchaser with respect to the
transactions contemplated by the Transaction Documents other than
as specified in the Transaction Documents.
3.2 Representations and Warranties
of the Purchasers . Each Purchaser hereby, for itself and for
no other Purchaser, represents and warrants as of the date hereof
and as of the Closing Date to the Company as follows:
(a)
Organization; Authority . Such Purchaser is an entity duly
organized, validly existing and in good standing under the laws of
the jurisdiction of its organization with the requisite corporate
or partnership power and authority to enter into and to consummate
the transactions contemplated by the applicable Transaction
Documents and otherwise to carry out its obligations hereunder and
thereunder. The execution, delivery and performance by such
Purchaser of the transactions contemplated by this Agreement have
been duly authorized by all necessary corporate or, if such
Purchaser is not a corporation, such partnership, limited liability
company or other applicable like action, on the part of such
Purchaser. Each of this Agreement and the Registration Rights
Agreement applicable to such Purchaser has been duly executed by
such Purchaser, and when delivered by such Purchaser in accordance
with the terms hereof, will constitute the valid and legally
binding obligation of such
|